Celcuity, Inc. (NASDAQ:CELC - Get Free Report) hit a new 52-week high during trading on Friday . The stock traded as high as $46.73 and last traded at $45.93, with a volume of 329271 shares trading hands. The stock had previously closed at $44.24.
Wall Street Analyst Weigh In
Several research firms have recently commented on CELC. Leerink Partners increased their price objective on Celcuity from $28.00 to $60.00 and gave the company an "outperform" rating in a report on Monday, July 28th. Needham & Company LLC reiterated a "buy" rating and issued a $29.00 price target on shares of Celcuity in a research note on Monday, July 28th. Stifel Nicolaus started coverage on shares of Celcuity in a research note on Tuesday, July 1st. They set a "buy" rating and a $30.00 price objective on the stock. Finally, HC Wainwright upped their target price on shares of Celcuity from $27.00 to $50.00 and gave the company a "buy" rating in a report on Monday, July 28th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $39.20.
Read Our Latest Stock Report on Celcuity
Celcuity Price Performance
The company has a current ratio of 6.61, a quick ratio of 6.61 and a debt-to-equity ratio of 1.14. The company has a 50 day moving average of $17.89 and a 200-day moving average of $13.18. The firm has a market capitalization of $1.83 billion, a P/E ratio of -15.51 and a beta of 0.68.
Celcuity (NASDAQ:CELC - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.86) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.95) by $0.09. On average, sell-side analysts predict that Celcuity, Inc. will post -2.62 EPS for the current year.
Insider Activity
In related news, Director David Dalvey sold 100,000 shares of the business's stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $43.98, for a total value of $4,398,000.00. Following the completion of the transaction, the director owned 125,000 shares of the company's stock, valued at $5,497,500. The trade was a 44.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 15.77% of the company's stock.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Baker BROS. Advisors LP grew its position in shares of Celcuity by 42.9% in the 4th quarter. Baker BROS. Advisors LP now owns 2,678,553 shares of the company's stock valued at $35,062,000 after buying an additional 803,575 shares during the last quarter. Ameriprise Financial Inc. boosted its holdings in Celcuity by 45.9% in the fourth quarter. Ameriprise Financial Inc. now owns 447,171 shares of the company's stock valued at $5,853,000 after acquiring an additional 140,642 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Celcuity by 16.2% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,725 shares of the company's stock worth $258,000 after purchasing an additional 2,756 shares during the last quarter. Corebridge Financial Inc. raised its holdings in Celcuity by 12.9% during the 4th quarter. Corebridge Financial Inc. now owns 16,256 shares of the company's stock worth $213,000 after purchasing an additional 1,858 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in Celcuity by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 1,651,981 shares of the company's stock valued at $21,624,000 after buying an additional 24,429 shares during the period. Institutional investors own 63.33% of the company's stock.
About Celcuity
(
Get Free Report)
Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Celcuity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celcuity wasn't on the list.
While Celcuity currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
